Abridge shares are not public exchange-traded shares. The healthcare AI company has raised about $830 million to date, most recently a $316 million Series E extension in April 2026 at a $5.3 billion valuation, the same valuation set by its $300 million Series E in June 2025. On June 11, 2026 co-founder and CEO Shiv Rao announced a strategic investment from Eli Lilly and a clinical-conversation model built with Nvidia, along with an expansion from clinical documentation into billing, payer and research workflows, as reported by Fortune, STAT and Healthcare Dive. No registration statement has appeared on SEC EDGAR as of the latest site review. Segmara shows a dated indicative mark for Abridge under a direct structure; any private transaction is subject to eligibility, availability, transfer approval, documentation, pricing and final terms.
Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases. Nothing here is investment advice.
Abridge started with ambient AI that drafts clinical notes and now positions itself as an operating layer for medicine, with more than 300 health systems reported live on the platform.
A strategic investment from Eli Lilly and a model partnership with Nvidia, both announced June 11, 2026, put it among the best-funded healthcare AI companies and on pre-IPO watchlists.
Abridge raises from venture and strategic investors through private placements; there is no company-run tender offer that outside buyers can join, and no per-share price from these rounds is public.
Any secondary route depends on seller supply, company transfer approval, accredited-investor eligibility and platform minimums.
Segmara lists Abridge with a dated indicative mark under a direct structure for research only. Segmara does not sell, broker, or arrange share purchases.
The answer stays conditional: access is subject to eligibility, availability, transfer approval, documentation and final terms, and the indicative mark is not an executable quote.
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
Indicative listing context
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | Private | Not reliably public | Do not invent a seed price when the source set is thin. |
| Growth rounds | Private | Company and market sources vary | Use public sources and official company releases. |
| Segmara listing | Current | $186.49/unit · as of September 4, 2026 | Indicative reference only, not a quote or an offer. |
| IPO status | Current | No public ticker shown here | Watch official company releases and the free Segmara IPO calendar. |
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /blog/how-to-buy-abridge-shares-before-ipo | Stable URL path for AI and search extraction. |
| Article title | How to Buy Abridge Shares Before IPO: Private-Market Access Basics | Main page topic. |
| Attached public sources | 7 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 51 | Live private-company listings in the public catalogue. |
| Priced listings | 37 | Catalogue listings with visible indicative or direct marks. |
| Listings without an indicative price | 14 | Catalogue listings where a public price is intentionally not invented. |
| Company | Abridge | Named company covered by this page. |
| Symbol label | ABRG | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | Healthcare AI | Catalogue sector used for comparison and internal linking. |
| Listing structure | Secondary | How the listing is categorized on Segmara. |
| Segmara mark | $186.49/unit · as of September 4, 2026 | Visible listing mark, or no indicative price yet. |
| Sector peer count | 1 | Number of live Segmara listings in Healthcare AI. |
| Structure peer count | 26 | Number of live Segmara listings categorized as Secondary. |
| Price rank | 14 of 37 | Ranked highest-to-lowest among Segmara listings with visible marks. |
| Price percentile | 65th | Percentile among visible Segmara catalogue marks. |
| Catalogue median mark | $92.58 | Median visible mark across priced Segmara listings. |
| Premium/discount to median | +101% | Difference between this listing mark and the catalogue median mark. |
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Formation | Private | Early ownership | The first value creation happens before ordinary public-market access. |
| Growth rounds | Private | Institutional repricing | Later rounds and tenders create the price history buyers study. |
| Segmara listing | Current | $186.49/unit · as of September 4, 2026 | Indicative reference only, not a quote or an offer. |
| Exit path | Future | IPO, tender, acquisition, or continued private status | Liquidity timing remains company-specific. |
| Chart metric | Score | Interpretation |
|---|---|---|
| Listing price percentile | 65 / 100 | $186.49/unit · as of September 4, 2026 ranks 14 of 37 priced listings |
Searches like 'How to Buy Abridge Shares Before IPO: Private-Market Access Basics' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara is an independent research site. It does not sell, broker, or arrange share purchases, and nothing on this page is investment advice.
Sources: SEC, March 3, 2025 · Investor.gov, October 14, 2022 · Regulation S-K Item 501 · SEC Form F-1.
Segmara Pro checks SEC EDGAR for Abridge filings every weekday and posts an alert in the members forum when one of these public filings appears. You can also check yourself with EDGAR full-text search.
Yes. The free Abridge tracker sends indicative marks by email, with no card and no documents. Segmara does not sell, broker, or arrange share purchases.
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes research simpler: anyone can follow named private companies for free, by email.
Open the free Abridge tracker first, email only. The IPO calendar is free, and Segmara Pro adds a weekly IPO brief.
There is no public Abridge ticker. Its rounds were placed with venture and strategic investors; any other private route would depend on eligibility, availability, documents and final terms.
Abridge's June 2025 Series E and April 2026 extension both valued the company at $5.3 billion; Eli Lilly's June 2026 strategic investment was announced without a valuation. Segmara does not turn any figure into a per-share price.
No. Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.
No registration statement has appeared on SEC EDGAR as of the latest site review, and the company's 2026 announcements did not address a listing.
Next step
The free tracker sends indicative marks by email. No card, no documents. Segmara does not sell, broker, or arrange share purchases.
Open the free tracker